Needham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $41

Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $38 to $41.